News
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283),
The Trump administration has canceled $766 million awarded to Moderna to develop a vaccine against potential pandemic ...
Health Secretary Robert F. Kennedy Jr. has repeatedly questioned the safety of mRNA technology, which is used in the ...
THURSDAY, May 29, 2025 (HealthDay News) — The U.S. government has canceled a $600 million contract with Moderna to develop a ...
The Trump administration has canceled a contract awarded to Moderna for the late-stage development of its bird flu vaccine ...
The US Department of Health and Human Services is terminating a contract with drugmaker Moderna to develop a vaccine to ...
The FDA approved Novavax’s COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.
H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna’s award ...
1don MSN
Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback